# 靶向Glypican-3的肝癌免疫治疗研究进展

余琳1.2王建华2\*\*葛良鹏 1,3,4\*\*（1重庆市畜牧科学院重庆402460 2重庆大学生物工程学院重庆400044)

（3 农业部养猪科学重点实验室 重庆 4024604 养猪科学重庆市市级重点实验室 重庆 402460）

摘要 磷脂酰肌醇蛋白聚糖3(Glypican-3)蛋白高特异性表达于肝细胞肝癌患者中，研究表明其与肝癌的发展和转移关系密切。目前以Glypican-3蛋白为靶点治疗肝癌的免疫研究主要包括治疗性抗体开发、CAR-T免疫疗法、免疫毒素及多肽疫苗等。现对Glypican-3 的结构功能与肝癌的关系进行介绍，并简要描述靶向Glypican-3 治疗肝癌的研究现状。

关键词 Glypican-3 肝癌 免疫治疗 抗体 CAR-T

癌症是威胁人类生命健康的重大疾病，据全球癌症数据调查显示，中国肝癌的病例数占全球的 $5 0 \% ^ { [ 1 ] }$ ，肝细胞肝癌（Hepatocellular carcinoma，HCC）占原发性肝癌的 $7 0 - 9 0 \% ^ { [ 2 ] }$ 。近年来，随着免疫治疗研究热，也有许多研究分子靶向药物以及治疗性抗体靶向治疗HCC，而索拉菲尼是目前上市的唯一治疗肝癌晚期的靶向药物[3,4]，因而，研究与开发肝癌特异性靶点药物具有重要意义。磷脂酰肌醇蛋白聚糖3（Glypican-3）是近年发现的HCC 细胞表面特异性膜蛋白，本文综述其结构功能及免疫治疗肝癌的研究进展。

# 1Glypican-3的结构和功能

Glypican-3，即磷脂酰肌醇蛋白聚糖3，是一种硫酸乙酰肝素蛋白类聚糖，通过细胞顶膜上的糖基磷脂酰肌醇（Glycosyl-phosphatidylinositol,GPI）锚定连接于细胞表面[5]。人Glypican-3 蛋白基因位于人染色体 Xq26上，编码 580 个氨基酸残基蛋白前体[6]。Glypican-3 核心蛋白约 $7 0 \mathrm { { k D a } }$ ，在358位精氨酸（Arg）和359位丝氨酸（Ser）之间，可被弗林蛋白酶裂解成一个 $4 0 \mathrm { { k D a } }$ 的氨基末端蛋白和一个与膜结合的30kDa羧基端蛋白[7]。核心蛋白羧基端蛋白的495位Ser和 509位Ser 分别连有一条硫酸乙酰肝素糖链（Heparan sulfate,HS)，参与生理功能的调节，而Glypican-3 蛋白 560 位的 Ser 被预测是与GPI结合的位置[8]。目前

Glypican-3蛋白还未能解析出晶体结构，基本结构见图1。

1988 年GPC3 基因在大鼠肠上皮细胞系中被Filmus 等首次检测到[9]。人Glypican-3蛋白在胎盘和胎儿发育期间表达于除神经系统外的大多数组织，如肝、肾、肺等，在成人器官中显著减少[10,I]。Giuseppe 等发现突变 Glypican-3 氨基酸会导致胎儿过度生长综合症（Simpson-Golabi-Behmel syndrome,SGBS）[12]，可能与GPC3的HS 链和成纤维生长因子2（FGF2）相互作用有关[13]。此后Mark等人也证明该蛋白基因丢失与 SGBS发生相关[14],Mariana 等研究认为Glypican-3作为负调节蛋白参与Hh信号通路也与 SGBS 的产生相关联[15]。

Glypican-3蛋白在不同发育时期表达不同，不同组织中表达量也有差异，尤其是在正常组织和癌组织中[11,16]，而不同癌组织中表达也差异显著，在胃癌、乳腺癌、卵巢癌和恶性间皮瘤中低表达或不表达[17-20],在HCC 中过度表达，与HCC发展和转移中密切相关[21,2]。目前许多研究认为Glypican-3蛋白是一种癌蛋白，在肝癌免疫治疗中具有很大潜力。

![](images/17578ff2d871783cba95ebe946cf3365d4e8158138eb2e39f12032d2fdbf52ce.jpg)  
图1Glypican-3 结构简图  
Fig.1Schematic structure of Glypican-3

# 2Glypican-3与肝细胞肝癌

Hus 等[23]对191例肝癌患者（ $7 4 . 8 \%$ HCC）mRNA样本进行分析，首次发现Glypican-3在成人肝癌患者中过表达；通过Northern 印迹分析结果显示在正常成人健康肝脏、局灶性结节性增肝和肝硬化中GPC3mRNA低表达或不存在，而在HCC 患者中异常高表达[24]；对HCC 患者组织进行免疫组化分析和可溶性Glypican-3蛋白N端免疫酶联分析结也表明该蛋白是肝癌重要的细胞及血清标记物[18,22,25,26]。

目前对于Glypican-3蛋白过表达诱导HCC 的机制复杂，没有完全清楚，但有几项研究结果也部分揭示了其可能致癌作用见图2。体内外实验研究[27-29]指出Glypican-3蛋白与Wnt 蛋白结合，促进Wnt与卷曲蛋白受体（Frizzled）的结合形成复合物，稳定了下游 $\beta$ -连环蛋白（ $\beta$ -catenin）在胞质内聚集，增强信号强度，进一步上调细胞核内相关转录因子（LEF/TLF)，促进C-myc 或其他癌基因表达，使其与GPC3启动子结合[30]；而同时研究还发现当Glypican-3 的表达水平提高又能促进C-myc 的表达，两者形成一个正反馈信号回路[31l，最终致使HCC 的发生与发展。Wu 等[32]研究提出，在HCC 患者中Glypican-3 蛋白与肿瘤上皮间质转化（Epithelial-mesenchymal transition,EMT）的发生紧密相关：细胞迁移侵袭试验中内源性高水平表达GPC3 的肝癌细胞 HepG2 相比Hep3B 和 Huh7具有更强转移、侵袭能力和EMT 样变化。

![](images/0b5c800621c06776b2804ff5d3e74abbe640dff085c95cbcd5da46b2c884a82d.jpg)  
图2Glypican-3促进HCC发展作用机制  
Fig.2Positive effectofGlypican-3 on HCC

# 3靶向Glypican-3的免疫治疗

# 3.1Glypican-3的治疗性抗体研究

Takahiro 等[-35]首次报道了抗人Glypican-3单克隆抗体GC33 (IgG2a,K)能够诱导抗体依赖的细胞介导的细胞毒性作用（Antibody-dependentcell-mediatedcytotoxicity,ADCC)，可作为肝癌患者的潜力药物。此人源化抗体GC33是通过人 Glypican-3蛋白COOH端的 40 个氨基酸免疫MRL/lpr小鼠筛选并人源化改造得到的单抗，能够明显抑制HepG2 和Huh7肝癌裸鼠肿瘤的生长；将GC33 的297位天冬酰胺突变后发现抗体的ADCC减弱，其抗肿瘤活性降低，同时也证明该单克隆抗体的抗肿瘤活性主要是介导了ADCC作用，产生了大量自然杀伤细胞。2016年GC33抗体完成临床二期试验，但在治疗晚期或转移性HCC患者疗效果不理想[36]。

Phung 等利用高通量流式分选的方法筛选出对HCC裸鼠移植瘤具有显著抑制的单抗YP7[37]。YP7是用人Glypican-3 肽段（511-560）免疫得到的鼠单克隆抗体，与HCC 细胞表面的Glypican-3 具有高亲和力，测得其平衡解离常数 $\mathrm { K _ { D } }$ 约 $0 . 3 \mathrm { n m o l / L }$ ，而与正常组织和其他原发性肝癌无作用。HN3是Feng 等利用噬菌体抗体库筛选得到的人源重链单域抗体，只含可变区VH与Fc 部分[38]。HN3能够特异性与Glypican-3核心蛋白结合，体外抑制肝癌细胞生长，可能是通过作用Yes 相关蛋白的信号通路阻滞细胞周期G1期，其给药剂量达到皮摩尔级;HN3也能对体内裸鼠瘤产生生长抑制效果。由于HN3分子量相对较小、亲和力高，研究报道将其作为药物载体靶向治疗HCC且比YP7更有优势[39]：将HN3与YP7抗体与光敏酞菁染料（IR700）偶联后给药GPC3阳性肿瘤小鼠，荧光观察发现HN3-IR700 组比YP7-IR700 组更快渗透到肿瘤组织。

HS20是特异性与Glypican-3蛋白HS糖链结合的单抗，通过下调Wnt信号通路产生抗肿瘤活性，研究还发现HS20也可能同时作用于Wnt3a及肝细胞生长因子（HGF)，从而抑制 HCC 细胞 Hep3B 和 Huh-7 的迁移、运动和增殖[40]。

# 3.2 Glypican-3的CAR-T免疫疗法

嵌和抗原受体 T 细胞疗法（Chimeric Antigen Receptor T-Cel Immunotherapy,CAR-T）已被证实是一种有效的肿瘤免疫治疗策略[41]，Gao 等[42]首次构建了靶向GPC3 的CAR-T 细胞，即基于GC33 单抗的 scFv 融合CD28、CD137和CD3ζ的第三代CAR-T，能诱导产生细胞因子IL-2和IFNγ，在体外试验表现出有效地裂解GPC3 阳性肝癌细胞，体内能抑制裸鼠Glypican-3 阳性的异位和原位移植瘤生长。

Jiang 等[43]利用人源性组织异位移植模型（Patient-derived tumor xenograft,

PDX）构建了三个不同Glypican-3 阳性的 HCC 病人PDX 肿瘤模型小鼠，使得保持了与原肿瘤的分化程度、形态特征及免疫学标志等，进而用第三代CAR-T技术构建抗Glypican-3 CAR-T 细胞能够有效作用于 HCC 细胞和 PDX 肿瘤。

“双抗原"CAR-T系统近年开发的一种更精准识别肿瘤T细胞改造技术[44],Glypican-3 和去唾液酸糖蛋白受体1两种蛋白均过表达于HCC 细胞表面，Chen等[45]构建了靶向这两种蛋白的CAR-T细胞，抗肿瘤实验结果表明该种T细胞能够高效刺激细胞因子（如IL-2、IFN-γ、TNF- $\mathbf { \nabla } \cdot \mathbf { a }$ 和 IL-4）分泌诱导肝肿瘤细胞的凋亡。

# 3.3Glypican-3的免疫毒素研究

免疫毒素是以植物毒素或细菌毒素为毒性分子，偶联抗体或细胞因子靶向杀伤肿瘤细胞。Gao 等[4实验室利用的Glypican-3 抗体YP7与HN3 分别融合绿脓杆菌毒素A（PE38)在体内外均具有抗肿瘤活性，并且发现HN3-PE38效果更佳。实验表明 HN3-PE38 能作用于 $\mathrm { W n / \beta }$ -catenin信号通路，同时也能通过Wnt3a蛋白间接抑制Yap 信号通路，进而抑制癌细胞生长。由于在小鼠体内，HN3-PE38 的抗肿瘤最低有效浓度为 $0 . 8 \mathrm { m g / k g }$ ，而这这一浓度已经对小鼠产生一定毒副作用，因而该实验室又进一步将PE38结构域ⅡI和II进行突变，去除B细胞抗原表位，降低其免疫原性，再与HN3抗体构建了重组免疫毒素 HN3-mPE24 和 HN3-HN3-mPE24[47]，仍保持具原抗肿瘤活性，裸鼠体内实验结果也显示能够耐受更高剂量免疫毒素，可作为治疗HCC的潜力药物。

# 3.4Glypican-3相关多肽疫苗研究

多肽疫苗是新一代疫苗研究的热点，在肿瘤免疫治疗中，可用已知肿瘤相关抗原或其衍生肽利用化学合成技术来制备疫苗。现已研究证明两个与人类主要组织相容性复合体（Human leukocyte antigen，HLA）I类结合的GPC3 限制性表位肽：GPC3298-306和GPC3144-152，以及一个与鼠主要组织相容性复合体（Histocompatibility-2，H2）结合的抗原肽： $\mathrm { \bf G P C } 3 _ { 1 2 7 - 1 3 6 }$ ，这几个多肽能与细胞毒性T淋巴细胞（Cytotoxic Tlymphocyte，CTL）结合发挥抗肿瘤作用[48-50]。

但临床上一些病人对GPC3多肽疫苗的治疗效果不佳[51]，因而该实验团队在此基础上利用脂质体（Liposome）作为疫苗佐剂[52]，将其与两个不同GPC3多肽偶联进行，并加入CpG 寡核苷酸，构建了 pGPC3(A2)-liposome/CpG 与pGPC3(B6)-liposome/CpG 疫苗进行小鼠接种，实验结果证明相比传统的不完全弗氏佐剂疫苗，其用量更低，同时能够更有效的激活CTL 细胞，在抑制裸鼠GPC3阳性肿瘤的的生长方面也具有良好的效果。

Table1Study of therapeutic antibodies targeting Glypican-3 in HCC   

<html><body><table><tr><td>名称</td><td>抗体类型</td><td>研究阶段</td><td>文献</td></tr><tr><td>GC33</td><td>IgG，人源化</td><td>临床二期 (已完成)</td><td>[33-36]</td></tr><tr><td>YP7</td><td>IgG，人源化</td><td>临床前</td><td>[37]</td></tr><tr><td>HN3</td><td>VH-hFc，全人源</td><td>临床前</td><td>[38]</td></tr><tr><td>HS20</td><td>scFv，全人源</td><td>临床前</td><td>[40,53]</td></tr><tr><td>ERY974</td><td>GPC3/CD3-bispecific</td><td>临床一期</td><td>https://clinicaltrials.gov/</td></tr><tr><td></td><td>antibody，人源化</td><td></td><td>NCT02748837</td></tr></table></body></html>

表1靶向Glypican-3的肝癌治疗性抗体研究  
表2临床靶向Glypican-3治疗肝癌的CAR-T研究  
Table2 Clinical study of CAR-T therapy targeting Glypican-3 in HCC   

<html><body><table><tr><td>临床标识号</td><td>开始时间</td><td>研究阶段</td><td>联合治疗</td><td>研究机构</td></tr><tr><td>NCT02395250</td><td>2015年3月</td><td>临床一期</td><td></td><td>上海仁济医院</td></tr><tr><td></td><td></td><td>（已终止）</td><td></td><td></td></tr><tr><td>NCT02723942</td><td>2015年6月</td><td>临床一期</td><td></td><td>广州复大肿瘤医院</td></tr><tr><td>NCT02715362</td><td>2016年3月</td><td>临床一期</td><td></td><td>上海吉凯基因化学公司</td></tr><tr><td>NCT03130712</td><td>2017年4月</td><td>临床一期</td><td></td><td>上海吉凯基因化学公司</td></tr><tr><td>NCT03146234</td><td>2017年3月</td><td>临床一期</td><td></td><td>上海仁济医院</td></tr><tr><td>NCT03084380</td><td></td><td></td><td></td><td>上海科济生物医药公司</td></tr><tr><td></td><td>2017年6月</td><td>临床一期</td><td>肝肿瘤经动脉化疗栓塞</td><td>重庆新桥医院</td></tr><tr><td>NCT02905188</td><td></td><td></td><td>(氟达拉滨、环磷酰胺)</td><td></td></tr><tr><td></td><td>2018年1月</td><td>临床一期</td><td>淋巴细胞删除性化疗（氟美国贝勒医学院</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr></table></body></html>

# 4总结与展望

在肿瘤临床治疗中，免疫靶向治疗作为一种配合手术、化疗等其他疗法的辅助手段，越来越受到重视。肿瘤免疫治疗可通过增强机体免疫反应，激发肿瘤特异性免疫，减少肿瘤的复发、转移，甚至治愈肿瘤[54]。Glypican-3 蛋白过表达于HCC 表面，还是具有巨大潜力作为靶点免疫治疗HCC，现已有几种在研的治疗性抗体见和Glypican-3的CAR-T细胞进入临床试验表1和表2。但有研究报道可溶性GPC3 能够抑制 HCC 细胞的增殖[55]，因而需要进一步研究Glypican-3 结构和功能的关系，探讨其致癌机制。有关可溶性Glypican-3蛋白以及Glypican-3多肽疫苗研究表明[7,56-58]，Glypican-3 作为早期或预后标志在肝癌辅助治疗中也具有重要意义。

目前，多靶点联合抑制肝癌或针对不同作用机制进行药物开发，如开发双功能抗体或多功能抗体、抗体偶联药物等，以及寻找更特异性的肝癌治疗靶点，联合肝移植、手术切除、化学疗法、放射疗法或介入疗法等其他疗法可能在肝癌治疗中取得更大成功。

# 参考文献

[1] TORRE L A, BRAY F, SIEGEL RL, et al. Global cancer statistics,2012 .CA: a cancer journal for clinicians, 2015,65(2): 87-108.   
[2] TORRE L A, SIEGEL R L, WARD E M, et al. Global Cancer Incidence and Mortality Rates and Trends--AnUpdate.Cancer epidemiology,biomarkers& prevention $\because$ a publication of the American Association for Cancer Research,cosponsored by the American Society of Preventive Oncology,2016,25(1): 16-27.   
[3] GALLE P R. Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. J Hepatol, 2008, 49(5): 871-873.   
[4] OHRI N, KAUBISCH A, GARG M, et al. Targeted Therapy for Hepatocellular Carcinoma. Semin Radiat Oncol, 2016,26(4): 338-343.   
[5]FILMUS J, SHI W, WONG Z M, et al. Identification of a new membrane-bound heparan sulphate proteoglycan. The Biochemical journal, 1995,311（Pt 2):561-565.   
[6]FILMUS J, CAPURRO M, RAST J. Glypicans. Genome biology, 2008, 9(5): 224.   
[7]HIPPO Y, WATANABE K, WATANABE A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Research, 2004,64(7): 2418-2423.   
[8] HO M, KIM H. Glypican-3: a new target for cancer immunotherapy. European journal of cancer, 2011,47(3): 333-338.   
[9]FILMUS J, CHURCH JG, BUICK R N. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Molecular and cellular biology,1988, 8(10): 4243-4249.   
[10] SONG HH, FILMUS J. The role of glypicans in mammalian development. Biochimica et biophysica acta,2002,1573(3): 241-246.   
[11] IGLESIAS B V, CENTENO G,PASCUCCELLI H, et al. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histology and histopathology,20o8,23(11): 1333-1340.   
[12] PILIA G, HUGHESBENZIE R M, MACKENZIE A, et al. Mutations in GPC3,a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genetics,1996,12(3): 241-247.   
[13] SONG HH, SHI W,FILMUS J. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. The Journal of biological chemistry,1997,272(12): 7574-7577.   
[14] VEUGELERS M, CAT B D, MUYLDERMANS S Y, et al. Mutational analysis of the GPC3/GPC4 glypican gene cluster on $\mathrm { X q } 2 6$ in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Human molecular genetics, 2000, 9(9): 1321-1328.   
[15] CAPURRO M1, XU P,SHI W,et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Developmental cell, 2008,14(5): 700-711.   
[16] FILMUS J. Glypicans in growth control and cancer. Glycobiology,2001, 11(3): 19R-23R.   
[17] XIANG Y Y, LADEDA V, FILMUS J. Glypican-3 expression is silenced in human breast cancer [J]. Onc0gene,2001,20(50): 7408-7412.   
[18] WICHERTA, STEGE A, MIDORIKAWA Y, et al. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene, 2004, 23(4): 945-955.   
[19] LIN H, HUBER R, SCHLESSINGER D, et al. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res,1999,59(4): 807-810.   
[20] MURTHY S S, SHEN T, DE RIENZO A, et al. Expression of GPC3,an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 20o0,19(3): 410-416.   
[21] SUNG Y K, HWANG S Y, PARK M K, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer science, 20o3,94(3): 259-262.   
[22] BAUMHOER D, TORNILLO L, STADLMANN S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. American journal of clinical pathology,2008,129(6): 899-906.   
[23] HSU H C, CHENG W, LAI P L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res, 1997, 57(22): 5179-5184.   
[24] ZHU Z W,FRIESS H, WANG L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 20o1, 48(4): 558-564.   
[25] YAMAUCHI N, WATANABE A, HISHINUMA M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern pathology : an offcial journal of the United States and Canadian Academy of Pathology, Inc, 2005,18(12): 1591-1598.   
[26] HARUYAMA Y, YORITA K, YAMAGUCHI T, et al. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer, 2015,137(7): 1643-1651.   
[27] CAPURRO M I, XIANG Y-Y,LOBE C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Research, 2005, 6245-6254.   
[28] CAPURRO M, MARTIN T, SHI W, et al. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. Journal of cel science, 2014,127(Pt 7): 1565-1575.   
[29] WANDS JR, KIM M. WNT/beta-catenin signaling and hepatocellular carcinoma. Hepatology, 2014, 60(2): 452-454.   
[30] HANN S R. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Seminars in cancer biology,20o6,16(4): 288-302.   
[31] LI L, JIN R, ZHANG X, et al. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology, 2012, 56(4): 1380-1390.   
[32] WU Y,LIU H, WENG H, et al. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. International journal of oncology, 2015,46(3): 1275-1285.   
[33] ISHIGURO T, SUGIMOTO M, KINOSHITA Y, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res,2008,68(23): 9832-9838.   
[34] NAKANO K, ORITA T, NEZU J, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun,2009, 378(2): 279-284.   
[35] NAKANO K, ISHIGURO T, KONISHI H, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.Anti-Cancer Drugs, 2010,21(10): 907-916.   
[36] ABOU-ALFA G K, PUIG O, DANIELE B, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. JHepatol, 2016,65(2): 289-295.   
[37] PHUNG Y, GAO W,MAN Y G, et al. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. mAbs, 2012, 4(5): 592-599.   
[38] FENG M, GAO W, WANG R, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences,2013,110(12): E1083-E1091.   
[39] HANAOKA H, NAGAYA T, SATO K, et al. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Molecular pharmaceutics, 2015,12(6): 2151-2157.   
[40] WONG C-M, GAO W, KIM H, et al. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PloS one,2015,10(9): e0137664.   
[41] COUZIN-FRANKEL J. Breakthrough of the year 2013. Cancer immunotherapy [J]. Science, 2013, 342(6165): 1432-1433.   
[42] GAO H, LI K,TU H, et al. Development of Tcells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 20(24): 6418-6428.   
[43] JIANG Z, JIANG X, CHEN S, et al. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Frontiers in immunology, 2016, 7:690.   
[44] ROYBAL K T, RUPP L J, MORSUT L, et al. Precision Tumor Recognition by T Cels With Combinatorial Antigen-Sensing Circuits. Cell, 2016,164(4): 770-779.   
[45] CHEN C, LI K, JIANG H, et al. Development ofT cels carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer immunology, immunotherapy $\because$ CII, 2017, 66(4): 475-489.   
[46] GAO W, TANG Z, ZHANG Y F, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nature communications, 2015, 6:6536.   
[47] WANG C, GAO W,FENG M, et al. Construction of an immunotoxin, HN3-mPE24,trgeting glypican-3 for liver cancer therapy. Oncotarget, 2017, 8(20): 32450-32460.   
[48] KOMORI H, NAKATSURA T, SENJU S, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006,12(9): 2689-2697.   
[49] MOTOMURA Y, IKUTA Y, KURONUMA T, et al. HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice. Int J Oncol, 2008,32(5): 985-990.   
[50] IWAMA T, HORIE K,YOSHIKAWA T, et al. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int J Oncol,2013, 42(3): 831-838.   
[51] SAWADA Y, YOSHIKAWA T, NOBUOKA D, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clinical cancer research : an oficial journal of the American Association for Cancer Research,2012,18(13): 3686-3696.   
[52] IWAMA T, UCHIDA T, SAWADA Y, et al. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic Tlymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochemical and Biophysical Research Communications,2016, 469(1): 138-143.   
[53] GAO W, KIMH,FENG M, et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60(2): 576-587.   
[54] NEVES H, KWOK HF. Recent advances in the field of anti-cancer immunotherapy. BBA clinical, 2015,3:280-288.   
[55] FENG M, KIM H, PHUNG Y, et al. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. International Journal of Cancer, 2011,128(9): 2246-2247.   
[56] WANG H L, ANATELLI F, ZHAI Q J, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocelllar mass lesions.Archives of pathology & laboratory medicine,2008,132(11): 1723-1728.   
[57] QIN Z, WANG J, WANG Y, et al. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection. Macromolecular bioscience, 2016,   
[58] SAWADA Y, YOSHIKAWA T, OFUJI K, et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology, 2016, 5(5): e1129483.

# Advance in Immunotherapy Research of Hepatocellular Carcinoma Targeting Glypican-3

YU Lin 1.2Wang Jian-hua²GE Liang-peng1,3.4

（1 Chongqing Academy of Animal Sciences，Chongqing 402460， China) (Bioengineering College of Chongqing University， Chongqing 40o044， China) (3 Key Laboratory of Pig Industry Sciences，Ministry of Agriculture，Chongqing402460, China) （3 Chongqing Key Laboratory of Pig Industry Sciences，Chongqing 402460， China)

Abstract Researchs shows that Glypican-3 expresses in hepatocellular carcinoma (HCC) patients with high specificity and is closely related to development of hepatocarcinoma. Including therapeutic antibody, Chimeric Antigen Receptor T-Cel Immunotherapy (CAR-T） , immunotoxin and vaccine are the focus of targeting Glypican-3 for immunotherapy in HCC at present. The structure and function of Glypican-3 is reviewed, as well as the progress of immunotherapy based on Glypican-3 in HCC is briefly described.

Key words Glypican-3 HCCimmunotherapy antibody CAR-T